GlaxoSmithKline, Stevenage, United Kingdom.
GlaxoSmithKline, Collegeville, PA, United States.
Front Immunol. 2018 Feb 5;9:153. doi: 10.3389/fimmu.2018.00153. eCollection 2018.
manipulations of autologous patient's cells or gene-engineered cell therapeutics have allowed the development of cell and gene therapy approaches to treat otherwise incurable diseases. These modalities of personalized medicine have already shown great promises including product commercialization for some rare diseases. The transfer of a chimeric antigen receptor or T cell receptor genes into autologous T cells has led to very promising outcomes for some cancers, and particularly for hematological malignancies. In addition, gene-engineered cell therapeutics are also being explored to induce tolerance and regulate inflammation. Here, we review the latest gene-engineered cell therapeutic approaches being currently explored to induce an efficient immune response against cancer cells or viruses by engineering T cells, natural killer cells, gamma delta T cells, or cytokine-induced killer cells and to modulate inflammation using regulatory T cells.
自体患者细胞或基因工程细胞治疗的操作，使得细胞和基因治疗方法得以发展，从而治疗原本无法治愈的疾病。这些个性化医疗模式已经显示出巨大的前景，包括一些罕见疾病的产品商业化。嵌合抗原受体或 T 细胞受体基因转移到自体 T 细胞中，为某些癌症，特别是血液恶性肿瘤带来了非常有希望的结果。此外，基因工程细胞治疗也在探索中，以诱导耐受和调节炎症。在这里，我们综述了目前正在探索的最新基因工程细胞治疗方法，通过工程化 T 细胞、自然杀伤细胞、γδ T 细胞或细胞因子诱导的杀伤细胞来诱导针对癌细胞或病毒的有效免疫反应，以及利用调节性 T 细胞来调节炎症。
